This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brandt, M. E.
Right arrow Articles by Smith, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brandt, M. E.
Right arrow Articles by Smith, M. T.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2004, p. 3363-3365, Vol. 42, No. 7
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.7.3363-3365.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

CASE REPORT

Fungemia Caused by Zygoascus hellenicus in an Allogeneic Stem Cell Transplant Recipient

Mary E. Brandt,1* Carol A. Kauffman,2 Peter G. Pappas,3 Naureen Iqbal,1 Beth A. Arthington-Skaggs,1 Wendy Lee-Yang,1 and Maudy T. Smith4

Mycotic Diseases Branch, Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia,1 Division of Infectious Diseases, Veterans Affairs Ann Arbor Healthcare System and University of Michigan Medical School, Ann Arbor, Michigan,2 Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama,3 Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands4

Received 29 January 2004/ Returned for modification 8 March 2004/ Accepted 22 March 2004

Zygoascus hellenicus (Candida hellenica) was isolated from a blood culture from a patient who had received an allogeneic stem cell transplant. The isolate displayed an antifungal susceptibility pattern of decreased susceptibility to fluconazole and itraconazole, high susceptibility to voriconazole, and low susceptibility to caspofungin. The organism was misidentified by a commercial yeast identification system. This is the first reported case of human infection with this rare ascomycetous yeast.


* Corresponding author. Mailing address: Mycotic Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd., Mailstop G-11, Atlanta, GA 30333. Phone: (404) 639-0281. Fax: (404) 639-3546. E-mail: mbb4{at}cdc.gov.


Journal of Clinical Microbiology, July 2004, p. 3363-3365, Vol. 42, No. 7
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.7.3363-3365.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.